306 related articles for article (PubMed ID: 26475333)
21. Atypical Chronic Myeloid Leukemia in Two Pediatric Patients.
Freedman JL; Desai AV; Bailey LC; Aplenc R; Burnworth B; Zehentner BK; Teachey DT; Wertheim G
Pediatr Blood Cancer; 2016 Jan; 63(1):156-9. PubMed ID: 26274939
[TBL] [Abstract][Full Text] [Related]
22. Analysis of gene mutation characteristics in patients with chronic neutrophilic leukaemia.
Yin B; Chen X; Gao F; Li J; Wang HW
Hematology; 2019 Dec; 24(1):538-543. PubMed ID: 31315541
[No Abstract] [Full Text] [Related]
23. CSF3R is mutated in chronic neutrophilic leukemia and atypical CML.
Cancer Discov; 2013 Jul; 3(7):OF23. PubMed ID: 23847367
[TBL] [Abstract][Full Text] [Related]
24. Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.
Dao KH; Solti MB; Maxson JE; Winton EF; Press RD; Druker BJ; Tyner JW
Leuk Res Rep; 2014; 3(2):67-9. PubMed ID: 25180155
[TBL] [Abstract][Full Text] [Related]
25. Identification of a novel CSF3R-SPTAN1 fusion gene in an atypical chronic myeloid leukemia patient with t(1;9)(p34;q34) by RNA-Seq.
Sheng G; Zhang J; Zeng Z; Pan J; Wang Q; Wen L; Xu Y; Wu D; Chen S
Cancer Genet; 2017 Oct; 216-217():16-19. PubMed ID: 29025591
[TBL] [Abstract][Full Text] [Related]
26. Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib.
Ammatuna E; Eefting M; van Lom K; Kavelaars FG; Valk PJ; Touw IP
Ann Hematol; 2015 May; 94(5):879-80. PubMed ID: 25491280
[No Abstract] [Full Text] [Related]
27. Mutational screens highlight glycosylation as a modulator of colony-stimulating factor 3 receptor (CSF3R) activity.
Hollander MJ; Malaker SA; Riley NM; Perez I; Abney NM; Gray MA; Maxson JE; Cochran JR; Bertozzi CR
J Biol Chem; 2023 Jun; 299(6):104755. PubMed ID: 37116708
[TBL] [Abstract][Full Text] [Related]
28. CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia.
Cui Y; Li B; Gale RP; Jiang Q; Xu Z; Qin T; Zhang P; Zhang Y; Xiao Z
J Hematol Oncol; 2014 Oct; 7():77. PubMed ID: 25316523
[TBL] [Abstract][Full Text] [Related]
29. Gain-of-function mutations in granulocyte colony-stimulating factor receptor (CSF3R) reveal distinct mechanisms of CSF3R activation.
Zhang H; Coblentz C; Watanabe-Smith K; Means S; Means J; Maxson JE; Tyner JW
J Biol Chem; 2018 May; 293(19):7387-7396. PubMed ID: 29572350
[TBL] [Abstract][Full Text] [Related]
30. [The clinical characteristics, gene mutations and prognosis of chronic neutrophilic leukemia].
Cui YJ; Jiang Q; Liu JQ; Li B; Xu ZF; Qin TJ; Zhang Y; Cai WY; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2017 Jan; 38(1):28-32. PubMed ID: 28219221
[No Abstract] [Full Text] [Related]
31. Current strategies in the diagnosis and management of chronic neutrophilic leukemia.
Otgonbat A; Zhao M
Chin Med J (Engl); 2014; 127(24):4258-62. PubMed ID: 25533830
[TBL] [Abstract][Full Text] [Related]
32. Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management.
Szuber N; Elliott M; Tefferi A
Am J Hematol; 2020 Feb; 95(2):212-224. PubMed ID: 31769070
[TBL] [Abstract][Full Text] [Related]
33. Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function.
Zhang H; Means S; Schultz AR; Watanabe-Smith K; Medeiros BC; Bottomly D; Wilmot B; McWeeney SK; Kükenshöner T; Hantschel O; Tyner JW
Cancer Res; 2017 Aug; 77(16):4258-4267. PubMed ID: 28652245
[TBL] [Abstract][Full Text] [Related]
34. Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors.
Lavallée VP; Krosl J; Lemieux S; Boucher G; Gendron P; Pabst C; Boivin I; Marinier A; Guidos CJ; Meloche S; Hébert J; Sauvageau G
Blood; 2016 Jun; 127(24):3054-61. PubMed ID: 27034432
[TBL] [Abstract][Full Text] [Related]
35. The molecular genetics of chronic neutrophilic leukaemia: defining a new era in diagnosis and therapy.
Elliott MA; Tefferi A
Curr Opin Hematol; 2014 Mar; 21(2):148-54. PubMed ID: 24335708
[TBL] [Abstract][Full Text] [Related]
36. Anti-inflammatory effects of ruxolitinib on chronic neutrophilic leukemia harboring
Sahara N; Yokoyama K; Matsunaga T; Kitahara S; Fujii T; Kobayashi S; Yusa N; Shimizu E; Imoto S; Tojo A; Ohno N
Leuk Res Rep; 2022; 18():100348. PubMed ID: 36119729
[TBL] [Abstract][Full Text] [Related]
37. Myeloid Disease with the CSF3R T618I Mutation after CLL.
Couto ME; Bizarro S; Sousa D; Domingues N; Oliveira I; Martins G; Teixeira MR; Mariz M
Case Rep Hematol; 2020; 2020():6670965. PubMed ID: 33414971
[TBL] [Abstract][Full Text] [Related]
38. [Emergence of mutation in the colony-stimulating factor 3 receptor gene during follow-up of unclassifiable myeloproliferative neoplasm].
Harada S; Okada K; Yokoyama S; Hidaka D; Hayase E; Onozawa M; Goto H; Hashimoto D; Kahata K; Endo T; Teshima T
Rinsho Ketsueki; 2021; 62(11):1609-1614. PubMed ID: 34866084
[TBL] [Abstract][Full Text] [Related]
39. Genomics of chronic neutrophilic leukemia.
Maxson JE; Tyner JW
Blood; 2017 Feb; 129(6):715-722. PubMed ID: 28028025
[TBL] [Abstract][Full Text] [Related]
40. Antineoplastic effects of pharmacological inhibitors of aurora kinases in CSF3R
Parducci NS; Garnique ADMB; Lima K; Carlos JAEG; Fonseca NP; de Miranda LBL; de Almeida BO; Rego EM; Traina F; Machado-Neto JA
Blood Cells Mol Dis; 2024 Jan; 104():102799. PubMed ID: 37839173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
